Novavax returns to quarterly profitability

 

 on Q4 2025 revenue of $147M, details Pfizer Matrix-M licensing terms including $30M upfront

• Novavax provides 2026 adjusted revenue framework of $230–$270 million range for its business
• Management targets reduced 2026 R&D and SG&A spending levels compared with prior expectations
• Pfizer Matrix-M licensing deal includes up to $500 million in additional milestone payments plus ongoing royalties to Novavax

https://finviz.com/quote.ashx?t=NVAX&p=d